Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results

by · The Markets Daily

Design Therapeutics (NASDAQ:DSGN – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06, FiscalAI reports.

Design Therapeutics Stock Performance

NASDAQ:DSGN traded up $0.29 during mid-day trading on Wednesday, hitting $10.63. The company had a trading volume of 314,980 shares, compared to its average volume of 441,931. Design Therapeutics has a fifty-two week low of $6.23 and a fifty-two week high of $17.25. The business’s fifty day moving average is $12.36 and its two-hundred day moving average is $12.14. The firm has a market cap of $665.23 million, a P/E ratio of -9.01 and a beta of 1.73.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DSGN. Wells Fargo & Company started coverage on shares of Design Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $26.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Design Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Design Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $17.86.

Read Our Latest Research Report on Design Therapeutics

Design Therapeutics Company Profile

(Get Free Report)

Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.

The company’s research has focused on disorders affecting the nervous system, muscles and eyes.

Further Reading